{
    "clinical_study": {
        "@rank": "95706", 
        "arm_group": [
            {
                "arm_group_label": "ruxolitinib, gemcitabine", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ruxolitinib, gemcitabine, nab-paclitaxel", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of ruxolitinib in combination with gemcitabine with or without\n      nab-paclitaxel to patients with advanced solid tumors that has two parts.\n\n      Part 1 of the study will evaluate the safety, tolerability and pharmacokinetics (PK) of\n      ruxolitinib when given as described to patients with advanced or metastatic solid tumors.  A\n      goal of Part 1 will be to identify the maximally tolerated dose (MTD) of ruxolitinib when\n      given with gemcitabine with or without nab-paclitaxel that will be used in Part 2 of the\n      study.\n\n      Part 2 of the study will further explore the safety, tolerability, PK, and preliminary\n      clinical activity of ruxolitinib at the dose identified in Part 1, in combination with\n      gemcitabine with or without nab-paclitaxel in subjects with advanced or metastatic\n      pancreatic cancer."
        }, 
        "brief_title": "An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Cancer", 
            "Metastatic Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Neoplasms", 
                "Neoplasms, Second Primary", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, 18 years or older\n\n          -  Histologically or cytologically confirmed solid tumor (Part 1) or  pancreatic cancer\n             (Part 2)\n\n          -  ECOG performance status \u2264 1\n\n          -  Received no more than 1 prior chemotherapy regimen for advanced or metastatic disease\n             (not including neo-adjuvant and/or adjuvant therapy. There is no restriction on the\n             number of prior non-myelosuppressive targeted therapies or hormonal agents (eg, EGFR\n             targeted therapy for lung cancer and hormonal therapy for breast cancer or ovarian\n             cancer); targeted and/or hormonal therapy alone will not be considered chemotherapy\n             for the purposes of this study.\n\n          -  Adequate renal, hepatic, and bone marrow function without blood product or\n             hematopoietic growth factor support:\n\n          -  Able to swallow and retain oral medication\n\n        Exclusion Criteria:\n\n          -  Any known contraindications to the use of gemcitabine (for enrollment in Regimen A or\n             B) or nab-paclitaxel (for enrollment into Regimen B).\n\n          -  Evidence of uncontrolled brain metastases or history of uncontrolled seizures.\n\n          -  Ongoing radiation therapy and/or radiation therapy administered within 28 days of\n             enrollment.  Subjects who have received radiation to the spine, pelvis, ribs, or\n             femur should be discussed with the sponsor, as extensive radiation to marrow forming\n             region may compromise a subject's ability to tolerate myelosuppressive chemotherapy.\n             Subjects who have ongoing radiotherapy-related toxicities are not eligible.\n\n          -  Subjects who participated in any other study in which receipt of an investigational\n             study drug occurred within 28 days or 5 half-lives (whichever is longer) prior to\n             first dose.\n\n          -  Current or previous other malignancy within 2 years of study entry, except cured\n             basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of\n             the cervix, or other noninvasive malignancy without sponsor approval.\n\n          -  Inability to swallow food or any condition of the upper GI tract that precludes\n             administration of oral medications.\n\n          -  Recent (\u2264 3 months) history of partial or complete bowel obstruction.\n\n          -  Unwilling to be transfused with blood components.\n\n          -  Known history of Hepatitis B or C infection or HIV infection.\n\n          -  Presence of \u2265 Grade 2 neuropathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01822756", 
            "org_study_id": "INCB 18424-144"
        }, 
        "intervention": [
            {
                "arm_group_label": "ruxolitinib, gemcitabine, nab-paclitaxel", 
                "description": "10 mg BID, 15 mg BID, 20 mg BID", 
                "intervention_name": "ruxolitinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ruxolitinib, gemcitabine", 
                    "ruxolitinib, gemcitabine, nab-paclitaxel"
                ], 
                "description": "1000 mg/m2\nOther names: Gemzar\u00ae", 
                "intervention_name": "gemcitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ruxolitinib, gemcitabine, nab-paclitaxel", 
                "description": "100 mg/m2, 125 mg/m2\nOther names: Abraxane\u00ae", 
                "intervention_name": "nab-paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ruxolitinib, gemcitabine", 
                "description": "5 mg BID, 10 mg BID, 15 mg BID, 20 mg BID", 
                "intervention_name": "ruxolitinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Incyte Corporation Call Center", 
            "phone": "1.855.463.3463"
        }, 
        "overall_official": {
            "affiliation": "Incyte Corporation", 
            "last_name": "Lance Leopold, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subjects will be assigned into cohorts, starting with Dose Level 0 in one of two treatment regimens, and escalating or de-escalating according to protocol criteria", 
            "measure": "Adverse events that are defined as dose limiting toxicities occurring in the first 28 days of treatment.", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01822756"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Plasma concentrations will be used to estimate peak plasma concentration (cmax) and area under the plasma concentration curve (AUC).", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 8"
            }, 
            {
                "measure": "Plasma concentration of tumor specific biomarkers and cytokines before and during treatment.", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Clinical activity as measured by the greatest decrease in tumor burden compared to baseline.", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 months"
            }
        ], 
        "source": "Incyte Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Incyte Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}